The GR-LEDGF/p75-HSP27 Axis Contributes to Cross-Resistance Between Enzalutamide and Docetaxel in Prostate Cancer

An emerging challenge in prostate cancer (PCa) treatment is the development of drug cross-resistance, wherein resistance to enzalutamide (ENZ), an androgen receptor signaling inhibitor (ARSI), also confers resistance to subsequent ARSI and docetaxel (DTX) treatments. The mechanisms underlying this d...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Pedro T. Ochoa, Evelyn S. Sanchez-Hernandez, Alfonso M. Duran, Kai Wen Cheng, Joel Philip, Tise Suzuki, Julia J. Unternaehrer, Julie Dutil, Bhaskar Das, Rituparna Ganguly, Yasmine Baca, David de Semir, Charles Wang, Isaac Kremsky, Carlos A. Casiano
Format:	Artigo
Sprog:	Inglês
Udgivet:	MDPI AG 2025-10-01
Serier:	Cells
Fag:	docetaxel drug cross-resistance enzalutamide glucocorticoid receptor HSP27 LEDGF/p75
Online adgang:	https://www.mdpi.com/2073-4409/14/19/1566
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!